Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H24N6O2 |
Molecular Weight | 368.4329 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(NC2=NC=NN3C=CC(CN4CC[C@@H](N)[C@H](O)C4)=C23)=CC=C1
InChI
InChIKey=CSGQVNMSRKWUSH-IAGOWNOFSA-N
InChI=1S/C19H24N6O2/c1-27-15-4-2-3-14(9-15)23-19-18-13(5-8-25(18)22-12-21-19)10-24-7-6-16(20)17(26)11-24/h2-5,8-9,12,16-17,26H,6-7,10-11,20H2,1H3,(H,21,22,23)/t16-,17-/m1/s1
Molecular Formula | C19H24N6O2 |
Molecular Weight | 368.4329 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20166197Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800025400 https://www.ncbi.nlm.nih.gov/pubmed/23490650
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20166197
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800025400 https://www.ncbi.nlm.nih.gov/pubmed/23490650
BMS-690514 is a potent, reversible oral inhibitor of epidermal growth factor receptor (EGFR/HER-1), HER-2 and -4, and vascular endothelial growth factor receptors (VEGFRs)-1 to -3 offering targeted inhibition of tumour growth and vascularisation in a single agent. Bristol-Myers Squibb was developing BMS 690514, as an oral treatment for cancer. BMS-690514 had being in phase II for the treatment of breast cancer; non-small cell lung cancer, but later these studies were discontinued.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20166197
Curator's Comment: BMS-690514 was able to cross the blood-brain barrier with a brain-to-plasma ratio of approximately 1.
Originator
Sources: http://adisinsight.springer.com/drugs/800025400
Curator's Comment: # Bristol-Myers Squibb
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL614102 |
9.0 nM [IC50] | ||
Target ID: CHEMBL3009 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21531814 |
60.0 nM [IC50] | ||
Target ID: CHEMBL1824 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21531814 |
19.0 nM [IC50] | ||
Target ID: CHEMBL1868 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21531814 |
50.0 nM [IC50] | ||
Target ID: CHEMBL279 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21531814 |
50.0 nM [IC50] | ||
25.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely [Inhibition 10 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/21673131/ |
likely | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/21673131/ |
likely | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/21673131/ |
no | |||
weak [IC50 >40 uM] | ||||
weak [IC50 >40 uM] | ||||
weak [IC50 >40 uM] | ||||
weak [IC50 >40 uM] | ||||
weak [IC50 >40 uM] | ||||
weak [IC50 >40 uM] | ||||
weak [IC50 >45 uM] | ||||
weak [IC50 >45 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/21673131/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/21673131/ |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major [Km ~1 uM] | no (pharmacogenomic study) Comment: No clinically relevant differences between poor and extensive metabolizers |
|||
major [Km ~23 uM] | yes (co-administration study) Comment: Ketoconazole increased dose-normalized Cmax and AUCinf by 55% and 127%. |
|||
major | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
unlikely | ||||
unlikely | ||||
unlikely | ||||
unlikely | ||||
unlikely | ||||
unlikely | ||||
unlikely | ||||
yes | ||||
yes | ||||
yes | yes (co-administration study) Comment: Ketoconazole increased dose-normalized Cmax and AUCinf by 55% and 127%. |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00743938
Tablets, Oral, 200 mg, once daily,
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21531814
Non–small cell lung tumor cells with exon 19 deletion
(HCC4006, HCC827, and PC9) were highly sensitive
to BMS-690514, which inhibits their proliferation with
IC50 values of 2 to 35 nmol/L. Breast and gastric tumor cell lines that have HER2 gene amplification (N87, SNU-216, AU565, BT474, KPL4, and HCC202) were inhibited with IC50 values of 20 to 60
nmol/L
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:53:46 GMT 2023
by
admin
on
Fri Dec 15 15:53:46 GMT 2023
|
Record UNII |
VKU5X213Q7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11349170
Created by
admin on Fri Dec 15 15:53:46 GMT 2023 , Edited by admin on Fri Dec 15 15:53:46 GMT 2023
|
PRIMARY | |||
|
100000178345
Created by
admin on Fri Dec 15 15:53:46 GMT 2023 , Edited by admin on Fri Dec 15 15:53:46 GMT 2023
|
PRIMARY | |||
|
859853-30-8
Created by
admin on Fri Dec 15 15:53:46 GMT 2023 , Edited by admin on Fri Dec 15 15:53:46 GMT 2023
|
PRIMARY | |||
|
C68832
Created by
admin on Fri Dec 15 15:53:46 GMT 2023 , Edited by admin on Fri Dec 15 15:53:46 GMT 2023
|
PRIMARY | |||
|
DB11665
Created by
admin on Fri Dec 15 15:53:46 GMT 2023 , Edited by admin on Fri Dec 15 15:53:46 GMT 2023
|
PRIMARY | |||
|
VKU5X213Q7
Created by
admin on Fri Dec 15 15:53:46 GMT 2023 , Edited by admin on Fri Dec 15 15:53:46 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545396
Created by
admin on Fri Dec 15 15:53:46 GMT 2023 , Edited by admin on Fri Dec 15 15:53:46 GMT 2023
|
PRIMARY | |||
|
SUB194073
Created by
admin on Fri Dec 15 15:53:46 GMT 2023 , Edited by admin on Fri Dec 15 15:53:46 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
URINE
|
||
|
TARGET -> INHIBITOR | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
FECAL
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
FECAL
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
FECAL
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
SINGLE DOSE |
|
||
Tmax | PHARMACOKINETIC |
|
SINGLE DOSE |
|
||